Roswell Park Comprehensive Cancer Center

Research team shares new data on how XPO1 blockade may boost immune-based treatments.

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Roswell Park researchers and partners shed light on how body composition at the time of diagnosis relates to mortality in epithelial ovarian cancer.

To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer. 

Sai Yendamuri, MD, MBA, FACS, has been appointed as Chief Strategy Officer and Senior Vice President of Business Development and Outreach.

Roswell Park Comprehensive Cancer Center earned top score of 100 on Human Rights Campaign Foundation survey.

A targeted therapy for children with high-risk Hodgkin lymphoma was shown to significantly reduce relapse rates when tested in a clinical trial conducted by the Children’s Oncology Group and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University.